General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...

Pfizer’s once-weekly antibody injection for haemophilia A and B, marstacimab, could be on track for regulatory approvals based on solid results in a phase 3 trial reported over the weekend ...

Pfizer reckons it will make a whopping $22 ... run out of money and had stopped accepting new doses as it needs a cash injection of $5.2 billion to keep operating. "Pfizer…has made more than ...

A jab given to patients to battle RSV through the NHS could potentially cause a disabling condition known as Guillain-Barré ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...

Pfizer said. In the study, patients were randomly chosen to receive a 300 milligram dose of sasanlimab as an under-the-skin injection in combination with the BCG vaccine, or just the BCG vaccine ...

Jan 13 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive ...

Pfizer plans to discuss these data with global ... Patients were randomized to receive sasanlimab 300 mg by subcutaneous (SC) injection every four weeks up to cycle 25 (cycle = four weeks ...

Pfizer believes sasanlimab has an edge even if competition arrives later, in part because the antibody is a simpler, lower-volume injection than other subcutaneous checkpoint inhibitors.

This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, AstraZeneca AZN and AbbVie announced their fourth-qua ...